In countries that have legislation, they have a number of things to encourage development. Some provide tax incentives for development. Some provide extended market exclusivity periods. There are also provisions for medications to be eligible for accelerated review, which we already have in Canada.
Those countries that have legislation have a number of components in that legislation. Our priority in Canada is to get the drugs here at the same time as they come to the U.S. or Europe. We are more focused on getting them into Canada and getting them through the regulatory process in the quickest and most efficient way, and working to also get access to them.